- #134: Framework for reimbursement decisions of digital health technologies (mHealth) and its (retrospective) application on selected examples
- #133: Effectiveness of Music Therapy for Autism Spectrum Disorder, Dementia, Depression, Insomnia and Schizophrenia
- #132b: Lung Cancer Screening in Risk Groups: A Review-Update of the Economic Evidence (Part II)
- #132a: Lung cancer screening in risk groups: A Systematic Review on Benefits/Harm and Information Strategies (Part 1)
- #130: Genetic Testing in the Context of Familial Hypercholesterolaemia Management: Organisational and ethical implications(part 1), and economic aspects (part 2)
- #129: Home-Treatment in Child and Adolescent Psychiatry: An Analysis of the Effectiveness and Possible Implementation in Austria
- #128: Robotics and functional electrical stimulation for stroke rehabilitation: A systematic review
- #127: Health Services Research in Oncology. Part I: End-of-Life Care
- #126: Health Services Research in Oncology: Patients with Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Therapy in Real-World Practice
- #6b: ATMPs und Gentherapien in Entwicklung
- #5: Eltern-Kind-Pass Update 2020/21 - Screenings zu psychischer Gesundheit, Ernährung und sozialer Kompetenz: Empfehlungen aus evidenzbasierten Leitlinien
- #4: Protonen- und Kohlenstoffionen Protonen und Kohlenstoffionen Therapie. Update zu Indikationen
- #3: Update PET/PET-CT Evidenz zum Bedarf und zur Planung bei inkologischen Indikationen
- #2: Covid-19: HSS/ Horizon Scanning Living Document
- #1: Update 12 months follow-up: Nusinersen in spinal muscular atrophy ("late onset") in children and adolescents ≥ 6 years
- DSD 123: Vascular-targeted photodynamic therapy with padeliporfin (Tookad® Soluble)
- DSD 122: Radiofrequency-Induced Intravesical Chemohyperthermia for Non-Muscle-Invasive Bladder Cancer
- DSD 121: Percutaneous Transvascular Implantation of a Coronary Sinus Reducing Stent
- DSD 120: Intrauterine ultrasound-guided transcervical radiofrequency ablation
- DSD 119: Implantation of a wireless pulmonary artery pressure sensor in patients with advanced heart failure’
- Update / DSD 106/1. Update 2020: Extracorporeal cytokine haemadsorption therapy in patients with sepsis or SIRS
- Update / DSD 97/2. Update 2020: Leadless pacemaker for right ventricle pacing
- #37/Update: Tucatinib (Tukysa®) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer
- #36/Update: Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer
- #35/2. Update: Moxetumomab pasudotox (Lumoxiti®) for the treatment of patients with relapsed or refractory hairy cell leukaemia (HCL)
- #34/Update: Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer
- #33/2. Update: Fedratinib (Inrebic®) for the treatment of primary and secondary myelofibrosis
- #32/Update: Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer
- #31/Update: Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma
- #30/Update: A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) for the treatment of early and metastatic breast cancer
- #29/Update: Carfilzomib (Kyprolis®) with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma (MM)
- #28/2. Update: Tagraxofusp (Elzonris®) in blastic plasmacytoid dendritic-cell neoplasm (BPDCN)
- #27/Update: Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of relapsed or refractory mantle cell lymphoma (MCL)
- #26/Update: Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC)
- #25/Update: Blinatumomab (Blincyto®) for the treatment of patients with Philadelphia chromosome positive B-precursor acute lymphoblastic leukaemia (ALL)
- #24/Update: Olaparib (Lynparza®) plus bevacizumab as first-line maintenance treatment in patients with ovarian cancer
- #23/Update: Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC)
- #22/Update: Niraparib (Zejula®) in patients with newly diagnosed advanced ovarian cancer
- #21/Update: Nivolumab (Opdivo®) plus ipilimumab (Yervoy®) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC)
- #20/Update: Atezolizumab (Tecentriq®) plus bevacizumab for the treatment of advanced or unresectable hepatocellular carcinoma (HCC)
- #19/Update: Ibrutinib (Imbruvica®) as a single agent or in combination with rituximab or obinutuzumab for the treatment of previously untreated chronic lymphocytic leukaemia (CLL)
- #18/Update: Durvalumab (Imfinzi®) in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)
- #17/3. Update: Belantamab mafodotin (Blenrep®) as monotherapy for the treatment of relapsed or refractory multiple myeloma (MM)
- #16/2. Update: Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST)
- #15/Update: Acalabrutinib (Calquence®) for the treatment of chronic lymphocytic leukaemia (CLL)
- #14: Carmustine (Carmustine Obvius®) as conditioning treatment before transplantation in patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphomas (NHL)
- #13/Update: Entrectinib (Rozlytrek®) for the treatment of patients whose solid tumours have a NTRK gene fusion, or patients with ROS1-positive advanced NSCLC
- #12/Update: Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer
- #11: Maintenance olaparib (Lynparza®) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer
- #10: Glasdegib (Daurismo®) with low-dose cytarabine (LDAC) in patients with newly diagnosed acute myeloid leukaemia (AML)
- #9: Daratumumab (Darzalex®) in a new pharmaceutical form associated with a new strength and a new route of administration for the treatment of multiple myeloma
- #8/Update: Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen
- #7: Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation
- #6: Isatuximab (Sarclisa®) plus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (MM)
- #5: Brentuximab vedotin (Adcetris®) with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCL)
- #4: Brigatinib (Alunbrig®) in ALK-positive non–small-cell lung cancer (NSCLC)
- #3: Rituximab (MabThera®) for the treatment of paediatric patients with previously untreated advanced stage CD20 positive DLBCL, BL, BAL, or BLL
- #2: Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC)
- #1: Venetoclax (Venclyxto®) and obinutuzumab in patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions